CHICAGO HIGHLIGHTS 2024 – BREAST ROUNDTABLE DISCUSSION: DESTINY-Breast07
OR
Chair
Dr. Christine Simmons
Panelists
Dr. Christine Brezden-Masley
Dr. Heather McArthur
This program has been made possible through unrestricted support from Eli Lilly
Studies/trials discussed:
- Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
